REVERSIR
DEAD

Serial Number

86776831

Owner

Alnylam Pharmaceuticals, Inc.

Attorney

Ann Lamport Hammitte

Filing Date

Oct 2, 2015

Add to watchlist:

No watchlists yet
View on USPTO

REVERSIR Trademark

Serial Number: 86776831

REVERSIR is a trademark filed by Alnylam Pharmaceuticals, Inc. on October 2, 2015. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Alnylam Pharmaceuticals, Inc. (91 trademarks)

300 Third Street, 3rd Floor
Cambridge, MA 02142

Entity Type: 03

Trademark Details

Filing Date

October 2, 2015

Registration Date

Not Registered

Published for Opposition

March 13, 2018

Goods & Services

Pharmaceutical preparations, namely, RNA therapeutics for use in the treatment of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection; Pharmaceuticals, biosimilars and biological preparations for medical and therapeutic purposes for use in the treatment of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Jun 14, 2021 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Jun 14, 2021 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 1, 2020 EXRA
SOU EXTENSION 5 GRANTED
Nov 30, 2020 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Nov 16, 2020 AITU
SOU EXTENSION 5 FILED
Nov 4, 2020 EXT5
SOU TEAS EXTENSION RECEIVED
Nov 4, 2020 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 8, 2020 EXRA
SOU EXTENSION 4 GRANTED
May 6, 2020 EX4G
SOU EXTENSION 4 FILED
May 6, 2020 EXT4
SOU TEAS EXTENSION RECEIVED
May 6, 2020 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 7, 2019 EXRA
SOU EXTENSION 3 GRANTED
Nov 5, 2019 EX3G
SOU EXTENSION 3 FILED
Nov 5, 2019 EXT3
SOU TEAS EXTENSION RECEIVED
Nov 5, 2019 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED
May 3, 2019 EXRA
SOU EXTENSION 2 GRANTED
May 1, 2019 EX2G
SOU EXTENSION 2 FILED
May 1, 2019 EXT2
SOU TEAS EXTENSION RECEIVED
May 1, 2019 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED
Nov 6, 2018 EXRA
SOU EXTENSION 1 GRANTED
Nov 2, 2018 EX1G
SOU EXTENSION 1 FILED
Nov 2, 2018 EXT1
SOU TEAS EXTENSION RECEIVED
Nov 2, 2018 EEXT
NOA MAILED - SOU REQUIRED FROM APPLICANT
May 8, 2018 NOAM
PUBLISHED FOR OPPOSITION
Mar 13, 2018 PUBO
NOTICE OF PUBLICATION
Feb 21, 2018 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 8, 2018 CNSA
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Aug 8, 2017 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Feb 2, 2017 RCSC
LETTER OF SUSPENSION MAILED
Aug 2, 2016 CNSL
SUSPENSION LETTER WRITTEN
Aug 1, 2016 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 26, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 26, 2016 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 26, 2016 TROA
NON-FINAL ACTION MAILED
Jan 27, 2016 CNRT
NON-FINAL ACTION WRITTEN
Jan 23, 2016 CNRT
ASSIGNED TO EXAMINER
Jan 22, 2016 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 7, 2015 NWOS
NEW APPLICATION ENTERED
Oct 6, 2015 NWAP